Suchergebnisse - "Mai, Elias K"

PubPharm (81)

1

Genomic Classification and Individualized Prognosis in Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Maura, F. | Rajanna, A. | Ziccheddu, B. | +34

2

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma : data from five randomized, controlled, phase III trials in 3700 patients

enthalten in: Leukemia | 2024

von Mai, E. | Hielscher, T. | Bertsch, U. | +26

3

Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma

enthalten in: European journal of nuclear medicine and molecular imaging | 2024

von Sachpekidis, C. | Enqvist, O. | Ulén, J. | +10

4

The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states

enthalten in: Journal of cancer research and clinical oncology | 2024

von Greinacher, A. | Kuehl, R. | Mai, E. | +6

5

The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states

enthalten in: Journal of cancer research and clinical oncology | 2024

von Greinacher, A. | Kuehl, R. | Mai, E. | +6

6

Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma

enthalten in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis | 2024

von Schreiner, S. | Berghaus, N. | Poos, A. | +10

7

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6) : results from a randomised, phase 3 trial

enthalten in: The lancet / Haematology | February 2024

von Mai, E. | Goldschmidt, H. | Miah, K. | +32

8

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6) : results from a randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2024

von Mai, E. | Goldschmid, H. | Miah, K. | +74

ErratumIn: Lancet Haematol. 2024 Feb 7;:. - PMID 38340740

9

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients : a single centre experience from the GMMG-HD6 and -HD7 trials

enthalten in: BMC cancer | 2023

von Kauer, J. | Freundt, E. | Schmitt, A. | +7

10

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384)

enthalten in: Cancers | 2023

von Boquoi, A. | Giagounidis, A. | Goldschmidt, H. | +7

1
2
3
4
5
6
7
8
9
Nächster »
[9]